Role of maintenance rituximab (Rituxan) therapy in the treatment of Follicular Lymphoma

P and T

Volumn 36, Issue 9, 2011, Pages 590-598

  Fowler, Nathan H ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Follicular lymphoma; Maintenance therapy; Rituximab

Indexed keywords

BENDAMUSTINE; CYCLOPHOSPHAMIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; ARTICLE; ASTHENIA; CANCER REGRESSION; CANCER RELAPSE; CHRONIC LYMPHATIC LEUKEMIA; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FOLLICULAR LYMPHOMA; HUMAN; INFECTION; LARGE CELL LYMPHOMA; LEUKOPENIA; MAINTENANCE THERAPY; NEUTROPENIA; OVERALL SURVIVAL; PATIENT SAFETY; PROGRESSION FREE SURVIVAL; RETREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 80052582855     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. American Cancer Society. Cancer Facts and Figures 2011. Available at: www.cancer.org/acs/groups/content/@epidemiology-surveilance/documents/document/acspc-029771.pdf. Accessed August 18, 2011.
2. Armitage JO. The changing classification of non-Hodgkin's lym- phomas. CA Cancer J Clin 1997;47(6):323-325.
3. Cheson BD, Gregory SA, Marcus R. Emerging treatments for in- dolent lymphoma. Clin Adv Hematol Oncol 2007;5(Suppl 8):1-9.
4. McLaughlin P. A look in the mirror. J Clin Oncol 2009;27(8):1158-1159.
5. Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: Results of the randomized phase III ECOG1496 study. J Clin Oncol 2009; 27(10):1607-1614.
6. Martinelli G, Schmitz SF, Utiger U, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010; 28(29):4480-4484.
7. Salles GA, Seymour JF, Feugier P, et al. Rituximab maintenance for 2 years in patients with untreated high tumor burden follicu- lar lymphoma after response to immunochemotherapy (Abstract 8004). J Clin Oncol 2010;28:(Suppl 15s).
8. van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Long-term outcome of the EORTC 20981 phase III ran- domized intergroup study. J Clin Oncol 2010;28(17):2853-2858.
9. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108(13):4003-4008.
10. Hainsworth JD, Litchy S, Shaffer DW, et al. Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma: A randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005;23(6):1088-1095.
11. Foá R, Di Rocco A, van Hazel G, et al. Maintenance rituximab every 2 months for 2 years is effective and well tolerated in patients with follicular lymphoma with both standard or rapid infusion: Updated results from the phase IIIb MAXIMA study (Abstract 3945). Blood 2010;116.
12. Vidal L, Gafter-Gvili A, Salles G, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: Systematic review and meta-analysis of randomized trials-2010 update (Abstract 1798). Blood 2010;116.
13. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lym- phoma Study Group. Blood 2005;106(12):3725-3732.
14. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Results of the GELA-GOELAMS FL2000 study. Blood 2008; 112(13):4824-4831.
15. Herold, M, Haas, A, Srock, S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study. J Clin Oncol 2007;25(15):1986-1992.
16. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lym- phoma. J Clin Oncol 2008;26(28):4579-4586.
17. Rummel, MJ, Norbert-Niederle, N, Maschmeyer, G, et al. Bendamustine plus rituximab is superior in respect of progression-free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Ger- many) (Abstract 405). Blood 2009;114(Suppl).
18. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitox-antrone (FCM) significantly increases the response rate and pro- longs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low- Grade Lymphoma Study Group. Blood 2004;104(10):3064-3071.
19. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non- Hodgkin's lymphoma, both in patients with and without rituximab during induction: Results of a prospective randomized phase III intergroup trial. Blood 2006;108(10):3295-3301.
20. van Oers MH. Rituximab maintenance therapy: A step forward in follicular lymphoma. Haematologica 2007;92(6):826-832.
21. Salles GA, Catalano J, Pierre Feugier P, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lym- phoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet 2011;377(9759):42-51.
22. Ardeshna KM, Smith P, Qian W, et al. An intergroup randomized trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2, and 3a): A preliminary analysis (Abstract 6). Blood 2010;116.
23. National Institutes of Health. Rituximab clinical trials. Available at: www.clinicaltrials.gov/ct2/show/NCT00075946. Accessed July 13, 2010.
24. Ghielmini, ME, Hsu Schmitz,S, Martinelli, G, et al. Long-term follow-up of patients with follicular lymphoma (FL) receiving single agent rituximab at two different schedules in study SAKK 35/98 (Abstract 8512). J Clin Oncol 2009;27(Suppl).
25. Taverna CJ, Bassi S, Hitz F, et al. Rituximab maintenance treatment for a maximum of 5 years in follicular lymphoma: Safety analysis of the randomized phase III trial SAKK 35/03 (Abstract 1802). Blood 2010;116.
26. Witzens-Harig M, Reiz M, Heiss C, et al. Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: Results of a prospective randomized controlled trial. Ann Hematol 2009;88(1): 51-57.
27. Habermann TM, Weller EA, Morison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24(19):3121-3127.
28. National Comprehensive Cancer Network clinical practice guidelines in oncology, non-Hodgkin's lymphoma. V.3.2011. Available at: www.nccn.org/professionals/physician_gls/pdf/nhl/pdf. Accessed August 23, 2010.
29. Li, YJ, Xia, ZJ, Li, S, et al. Maintenance rituximab versus observation after R-CHOP or R-EPOCH in patients with untreated poorprognosis diffuse large B-cell lymphoma and grade III follicular lymphoma (Abstract 8084). J Clin Oncol 2010;28(Suppl 15s).
30. National Institutes of Health. A multicentre, randomized phase III study of rituximab as maintenance treatment versus observation in patients with aggressive B-cell lymphoma: NHL-13. Available at: www.clinicaltrials.gov/ct2/show/NCT00400478?term=NHL-13&intr=rituximab&rank=1. Accessed August 23, 2011.
31. National Institutes of Health. Rituximab versus observation as maintenance therapy in chronic lymphocytic leukemia (chronic lymphocytic leukemia). Available at: www.clinicaltrials.gov/ct2/show/NCT01118234?term=maintenance&cond=CLL&intr=rituximab&rank=3. Accessed August 23, 2011.
32. National Institutes of Health. A study of maintenance treatment With MabThera (rituximab) in patients with progressive B-cell chronic lymphocytic leukemia. Available at: www.clinicaltrials.gov/ct2/show/NCT00718549?term=maintenance&cond=CLL&intr=rituximab&rank=10. Accessed August 23, 2011.
33. Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: First report of the National LymphoCare Study. J Clin Oncol 2009;27(8):1202-1208.
34. Flowers C, Taylor M, J. Hirata J, et al. Use of maintenance rituximab in the United States following R-based induction for follicular lymphoma (FL) (Abstract 8100). J Clin Oncol 2010;28(Suppl 15s).
35. Papadakis K, Follows G, Boyer J, et al. Cost-effectiveness analysis of rituximab maintenance in patients with untreated high tumour burden follicular lymphoma after response to immuno- chemotherapy: A UK National Healthcare Services perspective (Abstract 3833). Blood 2010;116.
36. Hayslip JW, Simpson KN. Cost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second remission. Clin Lymphoma Myeloma 2008; 8(3):166-170.
37. Pettengell E, Schmitz N, Gisselbrecht C, et al. Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy (Abstract 8005). J Clin Oncol 2010;28(Suppl 15s).